

Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090



Ref. :

Date :

NPL/SE/2021

Online filing at www.listing.bseindia.com

12th November, 2021

To,
The General Manager
DCS-CRD
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
MUMBAI - 400001

BSE CODE: 530119

Sub: Submission of the Standalone Un-Audited Financial Results alongwith the Statement of Assets & Liabilities and Cash Flow Statement and Limited Review Report for the Half year/Quarter ended 30th September, 2021 u/r 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir,

This is in continuation of our letter no. NPL/SE/2021 dated 1st November, 2021 regarding intimation of Board meeting for consideration and approval of the Standalone Un-Audited Financial Results alongwith the Statement of Assets & Liabilities and Cash Flow Statement and Limited Review Report thereon, for the Quarter/Half year ended 30th September, 2021.

Pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015 we are pleased to submit the following;

- Standalone Unaudited Financial Results for the half year/quarter ended 30th September, 2021;
- Standalone Limited Review Report by the Auditors for the half year/quarter ended 30th September, 2021;
- Standalone Statement of Assets & Liabilities for the half year ended 30th September, 2021;
- Standalone Statement of Cash flow for the half year ended 30th September, 2021.

which was considered and approved by the Board at their 4/2021-22 Meeting held on Friday, the 12th November, 2021.

The meeting of the board of directors commenced at 3:00 P.M. and concluded at 5:00 P.M.

The Financial Results will also be published in widely circulated English and Hindi (Vernacular) newspaper in the prescribed format for that purpose.

We are also in process of filing the aforesaid financial results in the XBRL format within the stipulated time and same shall be hosted on the Website of the Company.

You are requested to please take on record the above said documents for your reference and record.

Thanking You,
Yours Faithfully,

For, NATRAJ PROTEINS LIMITED


K.C. SHARMA
MANAGING DIRECTOR
DIN: 00012900

Enclosed: a/a



NATRAJ PROTEINS LIMITED

CIN: L00153MP1990PLC006090

Regd. Off. -Nagpur Kalan, Ordinance Factory Road, Itarsi, (M.P.)-461111

Ph No. 07572-262637, 262640, Fax No. 07572-262639

Email: natrajproteinltd@rediffmail.com

Statement of Standalone Un-Audited Financial Results for the quarter and Half-Year ended on 30th Sept., 2021

Part I		(Rs. In Lakhs except EPS)					
Statement of Standalone Unaudited Financial Results for the Quarter/half year Ended 30 th September, 2021							
S. No.	Particulars	Quarter			Half Year		Year
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	6 months ended	Corresponding 6 months ended in the previous year	Previous year ended
		30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income/Revenue from Operations	3487.65	2838.60	2918.15	6326.25	5300.92	14621.62
II	Other Income	2.46	13.26	2.00	15.72	3.51	10.60
III	Total Income (I+II)	3490.11	2851.86	2920.15	6341.97	5304.43	14632.22
IV	Expenses						
A	Cost of Materials consumed	1116.53	1288.41	1913.36	2404.94	4436.21	13884.53
B	Purchase of Stock-in-Trade	180.27	104.05	246.27	284.32	430.43	732.03
C	Changes in inventories of finished goods stock-in-trade and work-in-progress	1199.52	373.69	810.07	1573.21	466.56	(1089.66)
D	Employee benefits expense	19.48	37.91	28.52	57.39	57.60	118.34
E	Finance Costs	11.02	31.26	26.49	42.28	94.37	181.07
F	Depreciation and amortization expense	9.88	9.88	4.77	19.76	20.12	40.25
G	Other expenses	88.69	114.82	70.93	203.51	149.56	667.88
	Total Expenses (IV)	2625.39	1960.02	3100.41	4585.41	5654.84	14534.44
V	Profit/ (Loss) before exceptional items and Tax (I-IV)	864.72	891.84	(180.26)	1756.56	(350.41)	97.78
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) before tax (V-VI)	864.72	891.84	(180.26)	1756.56	(350.41)	97.78
VIII	Tax expense:						
	(1) Current Tax	219.82	202.10	-	421.92	-	12.96
	(2) Deferred Tax	(26)	22.53	-	(3.47)	-	(24.98)
	(3) Income tax related to earlier years	-	-	-	-	-	70.45
IX	Profit / (Loss) for the period from continuing operations (VII-VIII)	670.90	667.21	(180.26)	1338.11	(350.41)	39.35
X	Profit / (Loss) from Discontinuing operations	-	-	-	-	-	-
XI	Tax expenses of Discontinuing operations	-	-	-	-	-	-
XII	Profit / (Loss) from	-	-	-	-	-	-



	Discontinuing operations (after Tax) (X-XI)						
XIII	Profit / (Loss) for the period (IX+XII)	670.90	667.21	(180.26)	1338.11	(350.41)	39.35
XIV	Other Comprehensive Income:						
	A (i) Items that will not be reclassified to Profit or loss	4.67	6.97	1.47	11.64	4.25	5.07
	(ii) Income Tax relating to items that will not be reclassified to Profit or loss	-	-	-	-	-	(1.41)
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit/(Loss) and other Comprehensive Income for the period)	675.57	674.18	(178.79)	1349.75	(346.16)	43.01
XVI	Paid up Share Capital of the Company (Face Value Rs. 10/-)	374.70	374.70	374.70	374.70	374.70	374.70
XVII	Reserves excluding revaluation reserves	-	-	-	-	-	3231.98
XVIII	Earnings Per Share (for continuing operations)						
	(a) Basic	17.90	17.81	(4.81)	35.71	(9.35)	1.05
	(b) Diluted	17.90	17.81	(4.81)	35.71	(9.35)	1.05
XIX	Earnings Per Share (for Discontinued operations)						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XX	Earnings Per Share (for Discontinued and continuing operations)						
	(a) Basic	17.90	17.81	(4.81)	35.71	(9.35)	1.05
	(b) Diluted	17.90	17.81	(4.81)	35.71	(9.35)	1.05

Note :-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12th November, 2021.
- The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] as amended.
- The company operates in two segments i.e. solvent extraction and commodities derivative trading. However, for the current quarter as well as corresponding quarter in previous year there is no requirement of segmental reporting as the sales of commodities/derivatives are less than the threshold limits.
- The Standalone Statement of Assets and Liabilities as at 30th September, 2021 and the Statement of Cash Flow is provided as an annexure to this statement.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter/half year ended on 30th September, 2021. The report does not have any impact on the above results and notes which needs explanation.



6. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
7. Effective from 1st April, 2019, the company has adopted Indian Accounting Standard (IND-AS 116) "Leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1st April, 2021 and there was no material impact on financial results for the quarter ended on 30th September, 2021.
8. The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company and its Indian subsidiaries will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

For, NATRAJ PROTEINS LIMITED



KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900

Date: 12.11.2021
Place: Itarsi


STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS ON 30.09.2021

(Rupees in Lakhs)				
Statement of Assets and Liabilities	Particulars	Note No.	Figures as at the end of current reporting period 30.09.2021	Figures as at the end of previous reporting period 31.03.2021
I	2	3	4	5
		Un-Audited	Audited	
ASSETS				
(1) Non-Current Assets				
	(a) Property, Plant and Equipment		246.07	265.83
	(b) Capital Work-in-Progress		-	-
	(c) Investment Property		-	-
	(d) Goodwill		-	-
	(e) Other Intangible assets		-	-
	(f) Intangible assets under development		-	-
	(g) Biological Assets other than bearer plants		-	-
	(h) Financial Assets			
	i. Investments		-	-
	ii. Trade receivables		-	-
	iii. Loans		65.04	63.62
	iv. Others (to be specified)		-	-
	(i) Deferred tax assets (net)		-	-
	(j) Other non-current assets		637.91	190.36
	Total Non-Current Assets		949.02	519.81
(2) Current Assets				
	(a) Inventories		1700.76	4510.74
	(b) Financial Assets			
	i. Investments		235.00	-
	ii. Trade receivables		1769.36	1696.22
	iii. Cash and cash equivalents		1688.57	24.22
	iv. Bank balances other than (iii) above		-	-
	v. Loans		65.43	97.56
	vi. Other (to be specified)		18.77	-
	(c) Current Tax Assets (Net)		-	-
	(d) Other current assets		-	-
	Total Current Assets		5477.89	6328.74
	Total Assets		6426.91	6848.55
EQUITY AND LIABILITIES				
Equity				
	(a) Equity Share Capital		374.70	374.70
	(b) Other Equity		4581.73	3231.98
LIABILITIES				
(1) Non-current liabilities				
	(a) Financial Liabilities			
	(i) Borrowings		-	-
	(ii) Trade payables		-	-
	- Total outstanding dues of Micro and small enterprises;			
	- Total outstanding dues of creditors other than Micro and small enterprises;			
	(iii) Other Financial liabilities (other than those specified in item (b), to be specified)		-	-
	(b) Provisions		-	-
	(c) Deferred tax liabilities (Net)		58.36	61.83
	(d) Other non-current liabilities		-	-
	Total Non-Current Liabilities		58.36	61.83
(2) Current liabilities				
	(a) Financial Liabilities			
	(i) Borrowings		627.43	2217.62
	(ii) Trade payables		-	-
	- Total outstanding dues of Micro and small enterprises;			
	- Total outstanding dues of creditors other than Micro and small enterprises;		220.23	782.48
	(iii) Other Financial liabilities (other than those specified in item (c))		-	-
	(b) Other current liabilities		142.54	179.94
	(c) Provisions		-	-
	(d) Current Tax Liabilities (Net)		421.92	-
	Total Current Liabilities		1412.12	3180.04
	Total Equity and Liabilities		6426.91	6848.55

Date: 12.11.2021
Place: Itarsi

For, NATRAJ PROTEINS LIMITED

KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900



CASH FLOW STATEMENT FOR THE HALF-YEAR ENDED 30th SEPT., 2021

PARTICULARS	HALF-YEAR ENDED 30.09.2021	YEAR ENDED 31.03.2021
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax	1349.75	97.78
Adjustments for:		
ADD		
Depreciation & Amortization	19.76	40.24
Interest Charges	42.28	181.07
LESS		
Interest Income	15.71	8.67
CSR Expenses	0	0
Deferred Tax Asset	3.47	24.98
Operating Profit Before Working Capital Changes	1392.61	285.44
Adjustments for :		
Trade Receivables	(73.14)	88.44
Inventories	2809.98	(292.49)
Loans, Advances and other current assets	13.36	153.07
Current Liabilities	(222.72)	580.25
Income Tax Paid during the year	45.00	37.53
Total Adjustments	2572.48	566.80
CASH GENERATED FROM OPERATING ACTIVITIES (A)	3965.09	852.25
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed asset/ Capital WIP	(235.00)	(0.10)
Interest Received	15.71	8.67
Non Current Assets, Long term loans and advances	(448.97)	(21.61)
NET CASH USED IN INVESTING ACTIVITIES (B)	(668.26)	(13.04)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long Term Borrowings	0	0
Proceeds of Short Term Borrowings Banks	(1590.19)	(868.10)
Interest Paid	(42.28)	(181.07)
NET CASH (USED)/FROM FINANCING ACTIVITIES (C)	(1632.47)	(1049.18)
NET INCREASE/(DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	1664.35	(209.97)
Cash and Cash Equivalents - Opening Balance	24.22	234.19
Cash and Cash Equivalents - Closing Balance	1688.57	24.22
Increase/Decrease in Closing Cash Balance	(1664.35)	(209.97)
Note:		
Cash and Cash Equivalents include:		
(a) Cash on Hand	20.68	19.61
(b) Balances with Banks in Current Accounts	1667.89	4.61
(c) Balances in FDR with Bank - No lien deposits	0	0
	1688.57	24.22

Date: 12.11.2021
Place: Itarsi

For, NATRAJ PROTEINS LIMITED

KAILASH CHAND SHARMA
Chairman & Managing Director
DIN: 00012900





Limited Review Report on Quarterly/Half Yearly Unaudited Financial Results pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 Standalone

To,
The Board of Directors of
NATRAJ PROTEINS LIMITED
Itarsi (M.P.)

We have reviewed the accompanying statement of unaudited financial results ("the statement") of **NATRAJ PROTEINS LIMITED** ("the company") for the quarter/half year ended 30th September, 2021, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended including relevant circular issued by the SEBI from time to time.

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principals laid down in the Indian Accounting Standard-34 "Interim Financial Reporting" (IND AS-34), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

The company is not required to spend any fresh amount towards CSR for the period under review being the prescribed limits applicable to CSR has not been exceeded during the preceding 3 financial years. Further that the company the company is carrying the unspent amount of Rs.26.66 lakhs for the years 2014-2015, 2015-2016, 2016-2017.



The company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of receivables, unbilled revenues. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of the pandemic, the Company, as at the date of approval of these financial statements has used internal and external sources of information including subsequent payment received from debtors subsequent to the date of the financial statements. The company based on current estimates expects the carrying amount of these assets will be recovered with extended credit period.

Our conclusion is not modified in respect of these matters.

Place: Bhopal
Date: 12/11/2021



**For Anup Shrivastava & Associates
Chartered Accountants**

**CA Anup Shrivastava
(Partner)**

M. No. 075270

FRN: 006455C

UDIN: 21075270AAAAKS4782